Molecular Oncology, EarlyView.LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David +12 more
wiley +1 more source
Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy
Molecular Oncology, EarlyView.LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir +9 more
wiley +1 more source
Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy
Molecular Oncology, EarlyView.We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley +1 more source
Second-line medications for women aged 10 to 50 years with idiopathic generalized epilepsy
Importance: Women with idiopathic generalized epilepsy (IGE) face challenges in treatment due to limited options that are both effective and safe.Objective: To evaluate the effectiveness and safety of substitution monotherapy vs add-on therapy as second ...
Emanuele Cerulli Irelli (8639760) +5 more
core
The multifaceted roles of lysosomes in cancer
Molecular Oncology, EarlyView.Lysosomes support cancer cell adaptation by integrating macromolecule degradation and nutrient recycling with nutrient sensing, inter‐organelle communication and immune regulation. These interconnected functions can promote tumour growth, stress tolerance and therapy resistance, while also creating context‐dependent vulnerabilities that may be ...
Jia Li, Kevin M. Ryan
wiley +1 more source
FOLFIRI as second-line treatment of metastatic biliary tract cancer patients
Autopsy and Case Reports, 2019 The combination of cisplatin and gemcitabine is the standard first-line treatment of metastatic biliary tract cancer (BTC) patients. The benefit of second-line chemotherapy in these patients is controversial.
Rafael Caparica +3 more
doaj
Nivolumab—an effective second-line treatment for NSCLC [PDF]
Nature Reviews Clinical Oncology, 2015 openaire +2 more sources
Attitudes of cancer patients toward ctDNA‐based liquid biopsy for follow‐up
Molecular Oncology, EarlyView.This mixed‐methods study explored cancer patients' experiences, knowledge, and preferences regarding ctDNA‐based liquid biopsy for follow‐up. Awareness of ctDNA was low and recall of previous liquid biopsy was imperfect, yet acceptance was high.
Siddharth Chhajlani +7 more
wiley +1 more source
Pembrolizumab: A reliable second‐line treatment option for advanced esophageal cancer
Thoracic Cancer, 2022 Li Zheng +4 more
doaj +1 more source
Second-line treatment selection for advanced hepatocellular carcinoma: a network meta-analysis with reconstructed survival curves and integrated benefit-risk assessment. [PDF]
Front ImmunolLi X +8 more
europepmc +1 more source